相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What are the Options?
Jonathan E. Knikman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity
Seid Hamzic et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis
Bhavina B. Sharma et al.
ONCOLOGIST (2021)
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2020)
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
Forike K. Martens et al.
FRONTIERS IN PHARMACOLOGY (2020)
How can Australia integrate routine genetic sequencing in oncology: a qualitative study through an implementation science lens
Rosie O'Shea et al.
GENETICS IN MEDICINE (2020)
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
G. Argiles et al.
ANNALS OF ONCOLOGY (2020)
DPYDandUGT1A1Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation
Lisa A. Varughese et al.
PHARMACOTHERAPY (2020)
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
Bernhard Woermann et al.
ONCOLOGY RESEARCH AND TREATMENT (2020)
Severe Capecitabine Toxicity Associated With a Rare DPYD Variant Identified Through Whole-Genome Sequencing
Reynold C. Ly et al.
JCO PRECISION ONCOLOGY (2020)
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
Chara Stavraka et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report
Raffaele Palmirotta et al.
FRONTIERS IN ONCOLOGY (2019)
The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis
Anu Singh Maharjan et al.
CLINICAL COLORECTAL CANCER (2019)
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity
Vasileios Fragoulakis et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2019)
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice
Giuseppe Toffoli et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy
Linda M. Henricks et al.
EUROPEAN JOURNAL OF CANCER (2019)
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis
Linda M. Henricks et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals
Eiji Hishinuma et al.
DRUG METABOLISM AND DISPOSITION (2018)
Pharmacogenetic landscape of DPYD variants in south Asian populations by integration of genome-scale data
Judith M. Hariprakash et al.
PHARMACOGENOMICS (2018)
Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience
Con Murphy et al.
DOSE-RESPONSE (2018)
Genotype-guided fluoropyrimidine dosing: ready for implementation
Ursula Amstutz et al.
LANCET ONCOLOGY (2018)
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
Linda M. Henricks et al.
LANCET ONCOLOGY (2018)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update
Ursula Amstutz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
New advances in DPYD genotype and risk of severe toxicity under capecitabine
Marie-Christine Etienne-Grimaldi et al.
PLOS ONE (2017)
DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update
L. M. Henricks et al.
ANNALS OF ONCOLOGY (2017)
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time
Carin A. T. C. Lunenburg et al.
EUROPEAN JOURNAL OF CANCER (2016)
Meta-analysis of molecular targetted agents in the treatment of elderly patients with metastatic colorectal cancer: does the age matter?
ChuanJie Zhao et al.
JOURNAL OF CHEMOTHERAPY (2016)
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Maarten J. Deenen et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
Vijay M. Patil et al.
SOUTH ASIAN JOURNAL OF CANCER (2016)
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
Didier Meulendijks et al.
LANCET ONCOLOGY (2015)
Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score
Linda M. Henricks et al.
PHARMACOGENOMICS (2015)
Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity
Tanja K. Froehlich et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Comparative Functional Analysis of DPYD Variants of Potential Clinical Relevance to Dihydropyrimidine Dehydrogenase Activity
Steven M. Offer et al.
CANCER RESEARCH (2014)
Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis
Dan Rosmarin et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
A. Loganayagam et al.
BRITISH JOURNAL OF CANCER (2013)
Phenotypic Profiling of DPYD Variations Relevant to 5-Fluorouracil Sensitivity Using Real-time Cellular Analysis and In Vitro Measurement of Enzyme Activity
Steven M. Offer et al.
CANCER RESEARCH (2013)
A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated With Reduced DPD Enzyme Activity
S. M. Offer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
K. E. Caudle et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis
Salvatore Terrazzino et al.
PHARMACOGENOMICS (2013)
Pharmacogenetics: From Bench to Byte-An Update of Guidelines
J. J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
Ursula Amstutz et al.
PHARMACOGENOMICS (2009)
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer
Erick Gamelin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences
Keiko Maekawa et al.
JOURNAL OF HUMAN GENETICS (2007)
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals
K Seck et al.
CLINICAL CANCER RESEARCH (2005)
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
ABP van Kuilenburg
EUROPEAN JOURNAL OF CANCER (2004)
High prevalence of the IVS14+1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
ABP van Kuilenburg et al.
PHARMACOGENETICS (2002)
Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency:: High prevalence of the IVS14+1G>A mutation
ABP Van Kuilenburg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy et al.
ANNALS OF ONCOLOGY (2002)
Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations
JM Morsman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2000)
分享论文
